Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

• Status: Completed
• Trial end date: 2017-06-04

Summary

The purpose of this study is to determine the safety of regorafenib, an antiangiogenic drug, when combined with radioembolization using SIR-Spheres® microspheres in the treatment of colorectal cancer (CRC) that has spread to the liver.

• Phase: Phase 2

Details

• Lead Sponsor: SCRI Development Innovations, LLC
• Collaborator: Sirtex Medical